Inhibrx Schedules April 21 Webcast for Ozekibart CRC Phase 1/2 Update
Inhibrx will host a live webcast on April 21, 2026 at 1:30 p.m. PT to present Phase 1/2 clinical data on ozekibart (INBRX-109) combined with FOLFIRI in advanced or metastatic colorectal cancer. The webcast link will remain available for 60 days, and Inhibrx will update its corporate slide deck post-presentation.
1. Event Details
Inhibrx Biosciences will host a live webcast presentation on April 21, 2026 at 1:30 p.m. Pacific Time to share clinical findings from its Phase 1/2 study of ozekibart (INBRX-109) plus FOLFIRI in patients with locally advanced or metastatic, unresectable colorectal cancer. Investors and stakeholders can join via webinar or conference call using the provided dial-in information and conference ID.
2. Webcast Availability
The webcast will be accessible live and for replay for 60 days following the event. A link to the presentation will be maintained in the "Events and Presentations" section of Inhibrx’s website, ensuring continued access to clinical updates.
3. Corporate Presentation Update
Following the live webcast, Inhibrx will refresh its corporate presentation in the "Investors" section of its website, incorporating the latest clinical data and trial insights on ozekibart’s efficacy in combination with FOLFIRI.
4. Ozekibart Clinical Context
Ozekibart is a tetravalent DR5 agonist antibody engineered to trigger tumor-biased cell death. Its prior registrational ChonDRAgon trial in chondrosarcoma showed a 52% reduction in progression or death risk (HR 0.479; P<0.0001), more than doubling median PFS to 5.52 months versus 2.66 months for placebo.